National Drug Code

Natural Topical Pain-Reliever Proflexa Receives Official OTC Status

Retrieved on: 
Thursday, November 3, 2022
PPT, FDA, Technology, Spouse, National Drug Code, Pain, Sweeney, Machine learning, OTC, AI, NDC, Drug development, Hope, Medical device, Pharmaceutical industry, Amazon, Frankincense

FORT LAUDERDALE, Fla., Nov. 3, 2022 /PRNewswire/ -- Sinoveda is a Canadian-based health-science brand that is blazing an innovative trail toward the future of healthcare. The company has developed its patented PPT® technology, which utilizes a combination of in-vitro and in-silico testing, bringing the power of AI and machine learning to bear on the concept of natural and holistic medicine. One of Sinoveda's most popular PPT®-validated formulas thus far is its topical pain relief product Proflexa.

Key Points: 
  • One of Sinoveda's most popular PPT-validated formulas thus far is its topical pain relief product Proflexa .
  • Proflexa draws on the potent natural power of seven traditional medicinal herbs, including Clove, Dang Gui, Frankincense, and Hong Hua.
  • For example, one 60-patient survey conducted early on found that 90% of the subjects reported effective pain relief while using the topical.
  • In October of 2022, Proflexa officially received its NDC (National Drug Code) on the FDA website, formalizing its U.S. availability as an over-the-counter (OTC) drug.

Focus on Lymphoma App Gets New Look and Enhance Tools to Manage Lymphoma Diagnosis

Retrieved on: 
Friday, August 26, 2022
Android, Tablet, Caregiver, Technology, LRF, Research, CAR, SAB, Disease, Food, Apple, IPad, NDC, Checklist, Prescription, Foundation, National Drug Code, Food and Drug Administration Amendments Act of 2007, FDA, Lymphatic system, Google, Knowledge, Health, IPhone, Patient, Medical device, Lymphoma

NEW YORK, Aug. 26, 2022 /PRNewswire-PRWeb/ -- The Lymphoma Research Foundation – the nation's largest non-profit organization devoted exclusively to funding lymphoma research and serving the lymphoma community through education programs, outreach initiatives, and patient services – released features to Focus on Lymphoma, the first mobile application designed to help patients and caregivers better understand and manage their disease.

Key Points: 
  • "Focus on Lymphoma has become a vital resource for members of the lymphoma community, and this new update provides more ways patients and their loved ones can manage a lymphoma diagnosis," said Meghan Gutierrez, LRF Chief Executive Officer.
  • "Focus on Lymphoma provides the most up-to-date information on lymphoma, new tools to manage treatment, and easy access to the LRF Helpline for enhanced, individualized support and information."
  • The Foundation's app is an interactive and functional toolkit to help better navigate and manage a lymphoma diagnosis.
  • For more information or to download the Lymphoma Research Foundation's Focus On Lymphoma app, visit lymphoma.org/focusonlymphoma.

Fresenius Kabi, a Leader in Injectable Medicines, Introduces Data Matrix Barcodes on all Drugs as part of Companywide Commitment to Medication Safety

Retrieved on: 
Monday, August 8, 2022
Technology, Medical Supplies, Hospitals, Health Technology, Hardware, Health, Pharmaceutical, General Health, Data Management, Multimedia, GS1, Data collection, Patient safety, CEO, IV, Population, Technology, Data Matrix, National Drug Code, RFID, Health, Patient, Syringe, Fresenius (company), Medical Technology Group, Â, LinkedIn, Pharmacist, NDC, Pharmaceutical industry

Fresenius Kabi USA is the first pharmaceutical company to commit to offering GS1 Data Matrix barcodes on all drug product labels.

Key Points: 
  • Fresenius Kabi USA is the first pharmaceutical company to commit to offering GS1 Data Matrix barcodes on all drug product labels.
  • Data Matrix barcodes (also referred to as 2D or two-dimensional barcodes) store significantly more information than a standard one-dimensional barcode.
  • By adding GS1 Data Matrix barcodes to all product labels, we can help clinicians reduce manual data input, more accurately track medications, and reduce the potential for error.
  • To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/join-us and follow us on LinkedIn .

New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+

Retrieved on: 
Wednesday, April 6, 2022
Other Health, Pharmaceutical, Other Consumer, General Health, Women, Infectious Diseases, Seniors, Men, Clinical Trials, Science, Biotechnology, Consumer, Other Science, Health, Research, People, Risk, Company, Face, GSK, Amyris (company), Shingles, VZV, Vaccination, National Drug Code, Diagnosis, Korea Disease Control and Prevention Agency, Vaccine-preventable diseases, CDC, Sex, Plasma protein binding, COVID-19, Encounter, Research, Pain, Publication, Medicaid, Ageing, Varicella zoster virus, Health, Immunity, Chickenpox, MD, Immune system, Infection, Database, Person, Truven Health Analytics, Center, Rash, Annual report, Infectious Diseases Society of America, Patient, Disease, Pharmaceutical industry, Vaccine, Medicare

In this retrospective cohort study, people aged 50 or older who contracted COVID-19 were 15% more likely to develop shingles compared to controls who were never diagnosed with COVID-19.

Key Points: 
  • In this retrospective cohort study, people aged 50 or older who contracted COVID-19 were 15% more likely to develop shingles compared to controls who were never diagnosed with COVID-19.
  • The study observed adults aged 50 years and older using claims data from two large US databases and matched persons with and without COVID-19 using various known shingles risk factors.
  • The study authors, as well as case report publications , suggest that COVID-19 could trigger shingles by disrupting immune cells, allowing VZV to reactivate.
  • Individuals with a first-time COVID-19 diagnosis were matched with controls according to age, sex, shingles risk factors and healthcare costs.

Routine Vaccination Rates in Teens and Adults Continue to Lag Behind Pre-Pandemic Levels, Follow-up Analysis Shows

Retrieved on: 
Friday, January 21, 2022
Research, Infectious Diseases, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, CDC, Vaccine, Vaccination, Tetanus, Pneumonia, Patient, Shingles, Profile, Whooping cough, COVID-19, Pharmacy, Adult, FFS, DPT vaccine, Death, Meningitis, Disease, Part, Medicare Part D, Â, Medicaid, Diphtheria, HCPCS, Medicare (United States), CPT, Hepatitis B, Healthcare Common Procedure Coding System, GSK, Adolescence, National Drug Code, Inovalon, Medicare, Company, MD, Avalere Health, ACIP, Annual report, Hepatitis A, Green Cross (South Korean company), HPV, Current Procedural Terminology, Medicare Advantage, Pharmaceutical industry

This assessment follows two previous reports tracking the pandemics significant effect on routine vaccination.

Key Points: 
  • This assessment follows two previous reports tracking the pandemics significant effect on routine vaccination.
  • Cumulatively, adults and teens may have missed an estimated 37.1 million doses of recommended vaccines compared to 2019.
  • We know the ongoing pandemic presents challenges to important efforts to catch up and then exceed pre-pandemic vaccination levels, but we must not become complacent.
  • Diphtheria, tetanus, pertussis (Tdap) vaccine and an annual influenza shot are recommended for both teens and adults.

AmerisourceBergen Debuts RFID Tagging Service, Allowing Customers Nationwide To Purchase Pre-Tagged Product That Is Also Technology Agnostic

Retrieved on: 
Tuesday, December 14, 2021
Other Health, Software, Mobile, Wireless, Networks, General Health, Internet, Pharmaceutical, Data Management, Technology, Veterinary, Other Technology, Health, CIN, AmerisourceBergen, NDC, Solution, Pharmacy, RFID, National Drug Code, Risk, Wireless, Safety, Internet, Innovative Products of America, Efficiency, AB, Partnership, Senior, Technology, Health, RAIN, Security printing, Pharmaceutical industry

A first for the pharmaceutical supply chain, global healthcare company AmerisourceBergen (AB) today launched its RFID Tagging Service.

Key Points: 
  • A first for the pharmaceutical supply chain, global healthcare company AmerisourceBergen (AB) today launched its RFID Tagging Service.
  • Through this service, pharmacy customers nationwide can now choose to purchase product from AB that comes with radio-frequency identification (RFID) tags applied.
  • This technology-agnostic tagging service is enabled through an open-source model that freely discloses the tag decoding information to any interested technology provider.
  • This new solution relieves our manufacturer partners and pharmacy customers of the labor-intensive process of manually tagging product themselves, said Matt Wolf, Senior Vice President, Provider Solutions, AmerisourceBergen.

Pressure BioSciences Announces Launch of FDA-Registered Hand Sanitizer as First Product Developed Through Pending Merger Partners

Retrieved on: 
Thursday, May 14, 2020
Antiseptics, Hygiene, Health, Disinfectants, Skin care, Hand sanitizer, RTT, National Drug Code, Wine bottle

The custom-designed, next generation, premium hand sanitizer will be the first product released under the new holding company Availa Bio.

Key Points: 
  • The custom-designed, next generation, premium hand sanitizer will be the first product released under the new holding company Availa Bio.
  • The owners of privately held Cannaworx, Inc. have obtained FDA registration for the newly developed hand sanitizer, as well as an NDC (National Drug Code) number.
  • bottles, with 125 ml., 1 liter, and 1gallon sizes available by Fall 2020.The product contains 75% alcohol in a proprietary blend of other reagents.
  • According to a 2019 report by Radiant Insights, the global hand sanitizer market is expected to reach $5.5 billion by 2024 ( Click Here ).

Premier Inc. Celebrates a Year of Success in Eliminating Drug Shortages

Retrieved on: 
Wednesday, February 26, 2020
Surgery, Infectious diseases, Hospitals, FDA, Cardiology, Practice Management, Biotechnology, Pharmaceutical, Health, Oncology, Food and Drug Administration, Identifiers, National Drug Code, Shortage, Economy, Articles

Premiers comprehensive approach to addressing drug shortages includes partnerships with 25 leading manufacturers to reliably supply its members with nearly 150 shortage drugs by National Drug Code (NDC).

Key Points: 
  • Premiers comprehensive approach to addressing drug shortages includes partnerships with 25 leading manufacturers to reliably supply its members with nearly 150 shortage drugs by National Drug Code (NDC).
  • Guided by our member health systems, Premiers multi-faceted approach is eliminating drug shortages with both short- and long-term solutions that are increasing competition and improving the economic health of the market.
  • Premier identifies safe, high-quality supply sources for drugs that are or may be at risk of being added to the national drug shortage list.
  • After a period of decline, drug shortages in America increased significantly in 2018, according to the FDAs drug shortage list.

PeaceHealth addressing national drug shortages through Premier's ProvideGx™ program

Retrieved on: 
Tuesday, September 24, 2019
Food and Drug Administration, Market, Scarcity, Shortage, Workforce, National Drug Code, Health, Economy, Articles

As part of the effort, PeaceHealth will work through ProvideGx to source safe, high-quality drugs on the national drug shortage list, as well as those in categories that lack competition.

Key Points: 
  • As part of the effort, PeaceHealth will work through ProvideGx to source safe, high-quality drugs on the national drug shortage list, as well as those in categories that lack competition.
  • Some quick facts to consider related to chronic drug shortages:
    New drug shortages are rising up 27% in 2018 , according to an analysis by STAT.
  • Leveraging and guiding ProvideGx is the next step in PeaceHealth's ongoing effort with Premier to reliably source more than 250 high-quality products, including more than 100 shortage drugs by National Drug Code (NDC).
  • Premier has been at the forefront of combating drug shortages for years, working on behalf of its members to mitigate drug shortages and create new strategies for greater access.

Sandoz Inc. voluntarily recalls Losartan Potassium and Ezetimibe in prescription drug bottles in the U.S. due to failure to meet child-resistant closure requirements

Retrieved on: 
Thursday, August 29, 2019
Health, Clinical pharmacology, Pharmaceuticals policy, Pharmaceutical industry, Drugs, Medicinal chemistry, Pharmacy, Medical prescription, Prescription drug, Pseudoephedrine, National Drug Code, Tablet

At Sandoz, we take our responsibility for consumer safety very seriously.

Key Points: 
  • At Sandoz, we take our responsibility for consumer safety very seriously.
  • The only affected National Drug Code (NDC) numbers are #0781-5690-31 (30 tablets) and # 0781-5690-92 (90 tablets).
  • Consumers or pharmacies who have impacted prescription drug bottles with these NDC numbers in their homes or pharmacies should contact Sandoz at 1-800-525-8747 option # for free replacement child-resistant bottle caps.
  • Our purpose is to pioneer access to healthcare by developing and commercializing novel, affordable approaches that address unmet medical need.